Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H11N.C6H8O7 |
| Molecular Weight | 313.3032 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCC1=CC=CC=C1.OC(=O)CC(O)(CC(O)=O)C(O)=O
InChI
InChIKey=CTBJILANYAWODF-UHFFFAOYSA-N
InChI=1S/C8H11N.C6H8O7/c9-7-6-8-4-2-1-3-5-8;7-3(8)1-6(13,5(11)12)2-4(9)10/h1-5H,6-7,9H2;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
| Molecular Formula | C6H8O7 |
| Molecular Weight | 192.1235 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C8H11N |
| Molecular Weight | 121.1796 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
β-phenylethylamine (2-phenylethylamine) is a small amine containing alkaloid synonymous with phenethylamine and the acronym PEA; in the human body it has a neuromodulator/neurotransmitter role and is known as a trace amine due to its low quantity relative to other bioactive amino acids. PEA was characterized as a substrate for type B monoamine oxidase. PEA functions by activating trace amine receptors (including TAAR1 and TAAR2) thereby regulating monoamine turnover. Ring-substituted phenethylamines, commonly known as 2Cs, are designer drugs that are emerging as new drugs of abuse. PEA administration may be therapeutic in selected depressed patients.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Beta-phenylethylamines and the isoquinoline alkaloids. | 2001 Apr |
|
| Regulation of human monoamine oxidase B gene by Sp1 and Sp3. | 2001 Apr |
|
| beta-Phenylethylamine modulates acetylcholine release in the rat striatum: involvement of a dopamine D(2) receptor mechanism. | 2001 Apr 20 |
|
| Spectroscopic observation of intermediates formed during the oxidative half-reaction of copper/topa quinone-containing phenylethylamine oxidase. | 2001 Dec 25 |
|
| Use of beta-cyclodextrin in the capillary zone electrophoretic separation of the components of clandestine heroin preparations. | 2001 Jul 27 |
|
| A molecular approach to the study of structure-activity correlation for some amphetamines. | 2001 Jul-Sep |
|
| Involvement of adrenal medulla grafts in the open field behavior. | 2001 Jun |
|
| Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. | 2001 Mar 13 |
|
| Monoamine oxidase in developing rat renal cortex: effect of dexamethasone treatment. | 2001 Mar 9 |
|
| Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. | 2001 May |
|
| Platelet monoamine oxidase in healthy 9- and 15-years old children: the effect of gender, smoking and puberty. | 2001 Nov |
|
| Oxidation of phenethylamine derivatives by cytochrome P450 2D6: the issue of substrate protonation in binding and catalysis. | 2001 Nov 27 |
|
| High performance liquid chromatography with UV detection for the simultaneous determination of sympathomimetic amines using 4-(4,5-diphenyl-1H-imidazole-2-yl)benzoyl chloride as a label. | 2001 Oct |
|
| Oxygen dependency of monoamine oxidase activity in the intact lung. | 2001 Oct |
|
| Conserved tyrosine-369 in the active site of Escherichia coli copper amine oxidase is not essential. | 2001 Oct 30 |
|
| Postmortem tissue concentrations of venlafaxine. | 2001 Sep 15 |
|
| Probing the catalytic mechanism of Escherichia coli amine oxidase using mutational variants and a reversible inhibitor as a substrate analogue. | 2002 Aug 1 |
|
| [Localization of non-monoaminergic aromatic L-amino acid decarboxylase neurons (D-neurons) in the human striatum and their functional significance]. | 2002 Dec |
|
| Application of ligand SAR, receptor modeling and receptor mutagenesis to the discovery and development of a new class of 5-HT(2A) ligands. | 2002 Jun |
|
| Analysis of conserved active site residues in monoamine oxidase A and B and their three-dimensional molecular modeling. | 2002 May 10 |
|
| Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. | 2002 Nov 21 |
|
| Production of amines in equine cecal contents in an in vitro model of carbohydrate overload. | 2002 Oct |
|
| Major depressive episodes and diet pills. | 2002 Oct |
|
| Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. | 2003 Jan |
Sample Use Guides
Early research shows that taking 10-60 mg of phenethylamine by mouth per day along with 5 mg of the antidepressant selegiline (Anipryl, Eldepryl) twice per day for 4 weeks relieves depression in 60% of people. Of the people who respond to initial treatment with phenethylamine plus selegiline, 86% show continued depression relief when treated for up to 50 weeks.
Excretion study of phenethylamine in man: single oral dose of 300 mg.
Rats: 20, 40, 100 mg/kg ip or 1.0, 2.5, and 5.0 mg/kg iv
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:41:58 UTC 2023
by
admin
on
Sat Dec 16 18:41:58 UTC 2023
|
| Record UNII |
235L88TMD3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000090347
Created by
admin on Sat Dec 16 18:41:58 UTC 2023 , Edited by admin on Sat Dec 16 18:41:58 UTC 2023
|
PRIMARY | |||
|
235L88TMD3
Created by
admin on Sat Dec 16 18:41:58 UTC 2023 , Edited by admin on Sat Dec 16 18:41:58 UTC 2023
|
PRIMARY | |||
|
84473-65-4
Created by
admin on Sat Dec 16 18:41:58 UTC 2023 , Edited by admin on Sat Dec 16 18:41:58 UTC 2023
|
PRIMARY | |||
|
57354249
Created by
admin on Sat Dec 16 18:41:58 UTC 2023 , Edited by admin on Sat Dec 16 18:41:58 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|